Trial Information

A Phase IIa Trial of Sorafenib With Capecitabine and Oxaliplatin in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, with an annual
incidence of over 500,000 new patients and more than half of the new cases occur in China.
The most common etiological causes of HCC are hepatitis B and hepatitis C viral infections.

HCC is a cancer of high particular relevance in Hong Kong because of the high prevalence
(10%) of hepatitis B virus infection in the population. It is the second most common cancer
causing death in Hong Kong. Surgical resection and liver transplantation are regarded as the
main curative treatments for HCC. Nevertheless, the majority of patients have unresectable
HCCs because of advanced tumor stage and poor liver function. Besides, transplantation is
indicated only for early small HCCs, and its application is limited by the shortage of liver
graft, which is a particularly severe problem in Hong Kong.

HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there
is no effective systemic chemotherapy for HCC. Epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor (VEGF) are both overexpressed in HCC and thought to
contribute to tumor development. Oxaliplatin in combination with other chemotherapies or
biologic agents have been shown to be an effective and safe treatment in advanced HCC
patients. Sorafenib, an oral multi-kinase inhibitor, blocks tumor cell proliferation by
targeting multiple growth factor pathways and also exerts an anti-angiogenic effect.

Sorafenib has been approved by FDA for use in renal cell carcinoma based on prolonged
survival in phase III trials. Single agent Sorafenib has been shown to have some efficacy
in patients with advanced HCC and the primary result of prolonged overall survival have been
achieved in a recent randomized phase III trial. However, most patients would only have
disease stabilization as the phase II trial only showed a tumor response rate of only 8% (PR
& MR). Combination with chemotherapy may improve the tumor response rate.